Evaluating T cell-dependent bispecific antibodies with traditional endpoint killing assays fails to capture response kinetics and lacks the throughput needed to screen multiple parameters of activity. To overcome these bottlenecks, we developed an automated, high-throughput 384-well platform that enables concurrent kinetic tracking of target cell cytolysis, T cell activation, and multiplexed cytokine profiling. This integrated workflow leverages customized automation and advanced data analytics to streamline lead candidate selection and rapidly identify optimal combination therapies.

In this work, we developed a novel pipeline for engineering de novo miniproteins to target the Interleukin-4 receptor alpha (IL4Ra), a crucial receptor in Th2-mediated inflammatory diseases currently dominated by monoclonal antibodies. To achieve this, we used a scaffolding strategy to extract key cytokine helices and used RFdiffusion to design the connecting loops. Initial binders with sub-micromolar affinities were then optimized using molecular dynamics and phage display libraries for affinity maturation. Ultimately, this combined generative AI and directed evolution approach yielded high-affinity miniprotein binders, proving that diffusion models can successfully replicate complex cytokine interfaces for next-generation therapeutics.

Transcription factors and other intracellular protein-protein interactions remain challenging therapeutic targets. This presentation describes an integrated live-cell discovery platform combining genetically encoded peptide libraries, intracellular cyclisation, functional selection and scalable hit validation. By constraining peptides during selection, the workflow enriches cell-tolerated, biostable antagonists that disrupt transcription factor-DNA and protein-protein interactions. The approach links library design, screening, sequencing-based prioritization, biophysical characterization and cellular validation to accelerate discovery of functional, cell-active constrained peptides.

This presentation describes the integration of automated ÄKTA purification platforms into scalable protein-production workflows. By combining chromatography systems with autosamplers and adaptable, variable-driven methods, these platforms support automated purification across multiple production scales. The approach reduces manual intervention, increases processing capacity and provides the flexibility needed to accommodate diverse proteins, sample volumes and project requirements.